NEOSTIGMINE METHYLSULFATE INJECTION MARKET ANALYSIS

Market Challenges And Opportunities

The market is expected to face few restraints such as availability of alternative reversal agents like sugammadex sodium and strict regulatory guidelines for drug approval. Nonetheless, increasing research for expanding neostigmine methylsulfate injection therapeutic indications will create new opportunities. Moreover, growing geriatric population vulnerable to anticholinesterase poisoning also works in favor of the market growth.

Overall, rising anesthesia usage along with surgical procedures will boost the need for neuromuscular blockade reversal therapeutics. On the other hand, pricing pressure and limited research funding for neostigmine methylsulfate remain as challenges. Nonetheless, market players could benefit from collaborating with key opinion leaders and research institutes to strengthen their product portfolio.

Neostigmine Methylsulfate Injection Market Drivers

• Rising prevalence of diseases like myasthenia gravis and postoperative ileus requiring neostigmine: Neostigmine methylsulfate injection is primarily used as a cholinesterase inhibitor to treat various neurological disorders such as myasthenia gravis and postoperative urinary retention. The increasing prevalence of these conditions drives the demand for neostigmine methylsulfate injections. For instance, according to Myasthenia Gravis Foundation of America, publication ‘CLINICAL OVERVIEW OF MG’ published on 2021, the prevalence of myasthenia gravis reported in past 50 years for different regions is increasing, in the U.S. it is estimated at 14 to 20 per 100,000 population, and around 36,000 to 60,000 cases are in the U.S.
• Growing geriatric population vulnerable to conditions like postoperative ileus: The elderly population is more susceptible to neurological disorders, including myasthenia gravis, which often requires treatment with neostigmine methylsulfate injections. The growing geriatric population is one of the key factors driving the demand for neostigmine methylsulfate injection. Older adults aged 65 years and above are more susceptible to postoperative ileus, a temporary paralysis of the intestines following surgery. For instance, as per the data from the United Nations, the number of persons aged 65 years or over is projected to grow from 727.20 million in 2020 to 1.50 Billion in 2050 globally. This rising burden of aging population implies a higher number of older adults undergoing various surgical procedures annually.

Neostigmine Methylsulfate Injection Market Opportunities

• Emerging markets in developing countries: There is a significant opportunity for neostigmine methylsulfate injections in emerging markets, where healthcare infrastructure and access to essential medications are expanding. The increasing focus on improving healthcare facilities in countries across Asia Pacific, Latin America, and Africa creates a favorable environment for market growth. According to data from the World Bank, smartphone ownership in lower-middle income countries jumped from 22% to 50% from 2019 to 2021. This widens the potential customer base who can utilize RPM applications and connected health sensors. Younger demographics are especially receptive to new tools that make healthcare more convenient without requiring visits to crowded clinics or hospitals. Remote monitoring allows existing healthcare resources to stretch further by catching issues earlier and preventing costly hospitalizations.